“Use it or lose it” is the received wisdom when it comes to cognitive ability. But is there any truth in this old saw? Our latest study suggests that it depends how much “it” you have to start with.
Previous observational studies that looked at the effect of doing mentally stimulating activities, such as puzzles, on cognitive ability have largely supported the “use it or lose it” hypothesis. However, these studies have often been based on snapshots in time – so-called cross-sectional studies. To find out if there really is a link between mental engagement over a lifetime and cognitive ability in old age, you need to track people’s habits and mental abilities over a lifetime.
For our study, reported in The BMJ, we wanted to know if mental engagement protects against cognitive decline, or if those with a cognitive advantage engage more, giving the impression that this type of behaviour is responsible for their superior abilities. To answer these questions, we needed to work closely with our study participants and measure their intellectual abilities repeatedly over time and compare their abilities to their performance in early life.
Scotland is unique because in 1947 almost all 11-year-old children took the same mental ability test. The Scottish Council for Research in Education preserved these records and in 1998 allowed us to contact the surviving people who took the test.
We tested people living independently without dementia on up to five occasions over 15 years. Demographic, clinical, questionnaire and psychological data were recorded at all assessments and related to changes in performance on repeated verbal-memory and mental-speed tests.
Notable results
Our results are notable because they include childhood intelligence data from a rare historical survey of intelligence. They showed that, in late life, levels of mental ability are strongly linked to current levels of engagement in problem-solving.
Our study was able to account for childhood intelligence and education and revealed the rate of decline in cognition in late life did not differ between people who reported different levels of engagement. However, levels of engagement were associated with the performance at entry, aged 64.
Childhood intelligence was associated with intellectual engagement, which raises the question: do smarter people engage more, or are they smarter because they engage? If the latter were true in late life, then we would expect some influence on the rate of decline.
We have shown that intellectual engagement in this group of people without dementia is not related to later rates of cognitive decline. But engagement is linked to intellectual gain acquired from childhood to late middle age when we first started testing them. In other words, doing puzzles and other intellectually engaging things over a lifetime improves your IQ, so that when the inevitable cognitive decline sets in later life, you have a higher point to start from. The rate of decline is the same for all, regardless of the levels of engagement.
At this stage, we can foresee how lifelong intellectual engagement contributes to protection from falling below some intellectual threshold where you would be considered impaired. This is achieved by starting from a higher point.
Our findings are consistent with comparable studies that followed older people from age 50. We have identified problem-solving as being of specific importance. This suggests that interventions to boost resilience to ageing should include problem-solving components, such as reading complex novels, solving crossword puzzles and practising a musical instrument.


Why the future of marijuana legalization remains hazy despite high public support
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
Bank of America Maintains Forecast for Two Fed Rate Cuts in 2026 Despite Inflation Risks
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Strait of Hormuz blockade: the complex regional realities the US ignores at its peril 



